{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:18:31Z","timestamp":1793161111381,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Berlin Institute of Health"},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The 26S proteasome inhibitor bortezomib is currently used to treat multiple myeloma but also is effective in the treatment of antibody-mediated autoimmune disorders. One clinical concern is bortezomib\u2019s toxicity towards the (central) nervous system. We used standardized neuropsychological testing to assess cognitive function in six patients with myasthenia gravis and systemic lupus erythematodes before and after treatment with a mean cumulative dose of 9.4\u2009mg m\u22122 bortezomib. In addition, cognitive performance was measured in adult C57Bl\/6 mice after treatment with a human equivalent cumulative dose of 15.6\u2009mg m\u22122. Bortezomib concentrations were analysed in the human CSF as well as the brain tissue and serum of adult C57Bl\/6 mice at various time points after the injection of 1.3\u2009mg m\u22122 bortezomib with liquid chromatography\u2013tandem mass spectrometry. Neither patients nor mice showed signs of cognitive impairment after bortezomib therapy. Bortezomib concentrations in the human CSF and murine brain tissue reached only 5\u20137% of serum concentrations with comparable concentrations measured in the hippocampus and the neocortex. Five-fold higher concentrations were needed to damage neuronal cells in vitro. In conclusion, penetration of the intact blood\u2013brain barrier by bortezomib is low. Overall, our data show that bortezomib is a safe medication in terms of central nervous system toxicity.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaa021","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T14:50:24Z","timestamp":1582815024000},"source":"Crossref","is-referenced-by-count":37,"title":["Bortezomib at therapeutic doses poorly passes the blood\u2013brain barrier and does not impair cognition"],"prefix":"10.1093","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6825-7270","authenticated-orcid":false,"given":"Petra","family":"Huehnchen","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz f\u00fcr Neurologie, 10117 Berlin, Germany"},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, 10117 Berlin, Germany"},{"name":"Berlin Institute of Health (BIH), 10178 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Springer","sequence":"additional","affiliation":[{"name":"Gro\u00dfger\u00e4tezentrum BioSupraMol, Department of Biology, Chemistry and Pharmacy, Institute of Chemistry and Biochemistry, Freie Universit\u00e4t Berlin, 14195 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kern","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz f\u00fcr Neurologie, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Kopp","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz f\u00fcr Neurologie, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kohler","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz f\u00fcr Neurologie, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Medizinische Klinik mit Schwerpunkt f\u00fcr Rheumatologie und Klinische Immunologie, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Hiepe","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Medizinische Klinik mit Schwerpunkt f\u00fcr Rheumatologie und Klinische Immunologie, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz f\u00fcr Neurologie, 10117 Berlin, Germany"},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, 10117 Berlin, Germany"},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Center for Stroke Research Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-3894","authenticated-orcid":false,"given":"Wolfgang","family":"Boehmerle","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz f\u00fcr Neurologie, 10117 Berlin, Germany"},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, 10117 Berlin, Germany"},{"name":"Berlin Institute of Health (BIH), 10178 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Endres","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Klinik und Hochschulambulanz f\u00fcr Neurologie, 10117 Berlin, Germany"},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, NeuroCure Cluster of Excellence, 10117 Berlin, Germany"},{"name":"Berlin Institute of Health (BIH), 10178 Berlin, Germany"},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Berlin Institute of Health, Center for Stroke Research Berlin, 10117 Berlin, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"2020081109065936700_fcaa021-B1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/eji.201847492","article-title":"Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors","volume":"48","author":"Alexander","year":"2018","journal-title":"Eur J Immunol"},{"key":"2020081109065936700_fcaa021-B2","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1038\/cddis.2011.46","article-title":"Salinomycin induces calpain and cytochrome c-mediated neuronal cell death","volume":"2","author":"Boehmerle","year":"2011","journal-title":"Cell Death Dis"},{"key":"2020081109065936700_fcaa021-B3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00115-014-4126-3","article-title":"[Chemotherapy-induced neuropathy]","volume":"86","author":"Boehmerle","year":"2015","journal-title":"Nervenarzt"},{"key":"2020081109065936700_fcaa021-B4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.chroma.2014.04.024","article-title":"Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry","volume":"1345","author":"Clemens","year":"2014","journal-title":"J Chromatogr A"},{"key":"2020081109065936700_fcaa021-B5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2016.01.008","article-title":"CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy","volume":"88","author":"Foran","year":"2016","journal-title":"Neurobiol Dis"},{"key":"2020081109065936700_fcaa021-B6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/13825589708256642","article-title":"Effect of age on forward and backward digit spans","volume":"4","author":"Gr\u00c9Goire","year":"1997","journal-title":"Aging Neuropsychol Cogn"},{"key":"2020081109065936700_fcaa021-B284066058","article-title":"Influence of bortezomib on cognition in patients and C57Bl\/6 mice","author":"Huehnchen","year":"2020","journal-title":"Mendeley Data"},{"key":"2020081109065936700_fcaa021-B7","doi-asserted-by":"crossref","first-page":"e1185","DOI":"10.1038\/tp.2017.149","article-title":"A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL\/6 mice","volume":"7","author":"Huehnchen","year":"2017","journal-title":"Transl Psychiatry"},{"key":"2020081109065936700_fcaa021-B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/RHU.0000000000000210","article-title":"Refractory primary Sjogren syndrome successfully treated with bortezomib","volume":"21","author":"Jakez-Ocampo","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"2020081109065936700_fcaa021-B9","doi-asserted-by":"crossref","first-page":"e024523","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"key":"2020081109065936700_fcaa021-B10","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1523\/JNEUROSCI.4231-09.2010","article-title":"Impact of actin filament stabilization on adult hippocampal and olfactory bulb neurogenesis","volume":"30","author":"Kronenberg","year":"2010","journal-title":"J Neurosci"},{"key":"2020081109065936700_fcaa021-B11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/0961203317751859","article-title":"Cognitive functioning in systemic lupus erythematosus: a meta-analysis","volume":"27","author":"Leslie","year":"2018","journal-title":"Lupus"},{"key":"2020081109065936700_fcaa021-B12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1364-6613(00)01530-8","article-title":"Interdimensional interference in the Stroop effect: uncovering the cognitive and neural anatomy of attention","volume":"4","author":"MacLeod","year":"2000","journal-title":"Trends Cogn Sci"},{"key":"2020081109065936700_fcaa021-B13","first-page":"55523","article-title":"Assessment of spontaneous alternation, novel object recognition and limb clasping in transgenic mouse models of amyloid-\u03b2 and tau neuropathology","author":"Miedel","year":"2017","journal-title":"J Vis Exp"},{"key":"2020081109065936700_fcaa021-B14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nsmb.3389","article-title":"A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function","volume":"24","author":"Ramachandran","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"2020081109065936700_fcaa021-B15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.11-1-51","article-title":"A practical update on the use of bortezomib in the management of multiple myeloma","volume":"11","author":"San Miguel","year":"2006","journal-title":"Oncologist"},{"key":"2020081109065936700_fcaa021-B16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis","volume":"88","author":"Scheibe","year":"2017","journal-title":"Neurology"},{"key":"2020081109065936700_fcaa021-B17","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nprot.2006.115","article-title":"Clinical and empirical applications of the Rey-Osterrieth complex figure test","volume":"1","author":"Shin","year":"2006","journal-title":"Nat Protoc"},{"key":"2020081109065936700_fcaa021-B18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fnhum.2016.00473","article-title":"Effects of age on long term memory for degraded speech","volume":"10","author":"Thiel","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"2020081109065936700_fcaa021-B19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","article-title":"Trail making test A and B: normative data stratified by age and education","volume":"19","author":"Tombaugh","year":"2004","journal-title":"Arch Clin Neuropsychol"},{"key":"2020081109065936700_fcaa021-B20","first-page":"1","article-title":"Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models","volume":"15","author":"Wang","year":"2019","journal-title":"J Neurosurg"},{"key":"2020081109065936700_fcaa021-B21","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"2020081109065936700_fcaa021-B22","doi-asserted-by":"crossref","first-page":"12036","DOI":"10.1200\/jco.2006.24.18_suppl.12036","article-title":"Study of brain and whole blood PK\/PD of bortezomib in rat models","volume":"24","author":"Yu","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020081109065936700_fcaa021-B23","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaa021\/32677165\/fcaa021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/braincomms\/article-pdf\/2\/1\/fcaa021\/33639912\/fcaa021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/braincomms\/article-pdf\/2\/1\/fcaa021\/33639912\/fcaa021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T20:44:09Z","timestamp":1597178649000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaa021\/5762608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaa021","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020]]},"published":{"date-parts":[[2020,1,1]]},"article-number":"fcaa021"}}